SBIR Phase II: Improved Maternal Health with Predictive Patient Monitoring

SBIR 第二阶段：通过预测性患者监测改善孕产妇健康

• 批准号: 2233743
• 负责人: Courtney Williams
• 金额: $ 97.5万
• 依托单位: Emagine Solutions Technology
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-15 至 2025-11-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2233743&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Improved; Maternal

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to develop further a predictive model for health providers to address the life-threatening condition of preeclampsia in pregnant and postpartum patients. Preeclampsia affects 1 in 20 births, or 150,000 women in the U.S. each year. Not only does Preeclampsia cost 70,000 lives globally each year, it is also an expensive burden for healthcare systems. It costs nearly three times more to treat a patient with preeclampsia than one without this complication. When deployed at scale, the technology proposed in this SBIR grant could be a key factor to reducing maternal mortality in the United States, improving obstetric patient outcomes, reducing the cost of obstetric care, and helping to reduce health disparities.The proposed project will research and develop a method to potentially detect preeclampsia. Preeclampsia is a hypertensive disorder of pregnancy. This dangerous condition also costs the U.S. healthcare system $2.18 billion per year or one-third of the total amount spent on maternal healthcare in our country. Research objectives include optimizing a machine learning model, integrating patient-facing software into Electronic Health Records systems, implementing the predictive model for preeclampsia, integrating with peripheral wellness devices, developing reminder notification mechanisms, determining appropriate interface enhancements, and defining commercialization and regulatory strategies. Improving maternal health outcomes advances the general health and welfare of American families and can improve our country’s economic competitiveness on the world stage.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛的影响/商业潜力是为卫生提供者提供进一步的预测模型，以解决孕妇和产后患者的危及前美术状况。 preeclamsia每年影响20分之一，或美国15万名妇女。每年全球范围内，前美氏症不仅要花70,000人的生命，而且对于医疗保健系统来说，它也是昂贵的伯宁。治疗先兆子痫的患者比没有这种并发症的患者要花费几乎三倍。当大规模部署时，SBIR赠款中提出的技术可能是降低美国孕产妇死亡率，改善产科患者的结果，降低产科保健成本并帮助减少健康差异的关键因素。拟议的项目将研究和开发一种潜在检测前宾夕法尼亚的方法。 Precamia是一种高血压疾病。这种危险状况还使美国的医疗保健系统每年耗资21.8亿美元，或者是我国物质医疗保健支出的总额的三分之一。研究对象包括优化机器学习模型，将面向患者的软件集成到电子健康记录系统中，实施Precamia的预测模型，与外围保健设备集成，开发提醒通知机制，确定适当的接口增强功能以​​及定义商业化和监管策略。改善了遗嘱健康成果，可以改善美国家庭的一般健康和福利，并可以提高我们国家在世界舞台上的经济竞争力。该奖项反映了NSF的法定任务，并通过使用基金会的知识分子优点和更广泛的影响审查标准来评估，被认为是珍贵的支持。